StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD)

Research analysts at StockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a research report issued to clients and investors on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Stock Down 1.1 %

GLMD stock opened at $2.79 on Friday. The firm has a market cap of $1.79 million, a P/E ratio of -0.17 and a beta of 0.67. The company’s 50-day moving average price is $2.95 and its two-hundred day moving average price is $3.75. Galmed Pharmaceuticals has a 12 month low of $2.56 and a 12 month high of $23.80.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.